Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers

作者：Eshan U. Patel, Evan M. Bloch, William Clarke, Yu‐Hsiang Hsieh, Denali Boon, Yolanda Eby, Reinaldo E. Fernández, Owen R. Baker, Morgan Keruly, Charles Kirby, Ethan Klock, Kirsten Littlefield, Jernelle Miller, H Schmidt, Philip A. Sullivan, Estelle Piwowar‐Manning, Ruchee Shrestha, Andrew D. Redd, Richard E. Rothman, David Sullivan, Shmuel Shoham, Arturo Casadevall, Thomas C. Quinn, Andrew Pekosz, Aaron A.R. Tobian, Oliver Laeyendecker · 发表于：Journal of Clinical Microbiology · 年份：2020 · DOI：10.1128/jcm.02257-20 · 被引用次数：199 · 研究领域：SARS-CoV-2 and COVID-19 Research、SARS-CoV-2 detection and testing、COVID-19 Clinical Research Studies

Accurate serological assays to detect antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed to characterize the epidemiology of SARS-CoV-2 infection and identify potential candidates for coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) donation. This study compared the performances of commercial enzyme immunoassays (EIAs) with respect to detection of IgG or total antibodies to SARS-CoV-2 and neutralizing antibodies (nAbs). The diagnostic accuracy of five commercially available EIAs (Abbott, Euroimmun, EDI, ImmunoDiagnostics, and Roche) for detection of IgG or total antibodies to SARS-CoV-2 was evaluated using cross-sectional samples from potential CCP donors who had prior molecular confirmation of SARS-CoV-2 infection ( n = 214) and samples from prepandemic emergency department patients without SARS-CoV-2 infection ( n = 1,099).